AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.
Testosterone replacement in hypogonadal men improves body composition, mood, and sexual functioning. In this 90-d study, we compared the pharmacokinetics and treatment effectiveness of a topical testosterone gel (AA2500) at two concentrations, 50 mg/d and 100 mg/d, to a testosterone patch and placebo gel in 406 hypogonadal men. Pharmacokinetic profiles were obtained, body composition was measured, and mood and sexual function were monitored. AA2500 treatments resulted in dose-dependent improvements in all pharmacokinetic parameters, compared with testosterone patch and placebo. Mean average concentrations at d 90 T were 13.8, 17.1, 11.9, and 7.3 nmol/liter for 50 mg/d AA2500, 100 mg/d AA2500, testosterone patch, and placebo, respectively. At d 90, the 100 mg/d AA2500 treatment improved lean body mass by 1.7 kg and percentage of body fat by 1.2% to a significantly greater degree than either control treatment. Significant improvements in spontaneous erections, sexual desire, and sexual motivation were also evidenced with the 100 mg/d AA2500 dose in comparison with placebo. Testosterone gel was well tolerated; however, the testosterone patch resulted in a high rate of application site reactions. Overall, AA2500 is an effective, well tolerated treatment for hypogonadism.
Steidle
C
C
Northeast Indiana Research, Fort Wayne, Indiana 46825, USA. chrisste@aol.com
Schwartz
S
S
Jacoby
K
K
Sebree
T
T
Smith
T
T
Bachand
R
R
D000279:Administration, Cutaneous; D000339:Affect / Q000187:drug effects; D000368:Aged; D000375:Aging / Q000502:physiology*; D000728:Androgens / Q000097:blood*; D001823:Body Composition / Q000187:drug effects*; D013196:Dihydrotestosterone / Q000097:blood; D004311:Double-Blind Method; D003875:Drug Eruptions / Q000453:epidemiology; D005782:Gels; D006801:Humans; D015994:Incidence; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000032:analysis; D012449:Safety; D012725:Sexual Behavior / Q000187:drug effects*; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000728:Androgens; D005782:Gels; D008055:Lipids; D013196:Dihydrotestosterone; D013739:Testosterone; D017430:Prostate-Specific Antigen